Inhalative administration of fibrinogen IIb/IIIa receptor antagonists for prompt acute therapy in the event of thrombus formatio
The effect of the intravenously administered fibrinogen IIb/IIIa receptor antagonist Tirofiban as a thrombocyte aggregation inhibitor is known and well investigated. Now, for the first time, the dispersal of Tirofiban in the form of an aerosol has been achieved, which allows application of the produced aerosol via inhalation. This has the advantage that the active ingredients are reabsorbed very quickly after deposition and rapidly reach a therapeutically active drug level in the blood, which leads to life-saving thrombocyte aggregation inhibition. With this the possibility for acute and immediate treatment of diseases which are caused by or in conjunction with thrombus formation is finally available.
Further Information: PDF
TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12
Contact
Dr. Peter Stumpf
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Properties of new materials for microchips
… can now be measured well. Reseachers of Delft University of Technology demonstrated measuring performance properties of ultrathin silicon membranes. Making ever smaller and more powerful chips requires new ultrathin…
Floating solar’s potential
… to support sustainable development by addressing climate, water, and energy goals holistically. A new study published this week in Nature Energy raises the potential for floating solar photovoltaics (FPV)…
Skyrmions move at record speeds
… a step towards the computing of the future. An international research team led by scientists from the CNRS1 has discovered that the magnetic nanobubbles2 known as skyrmions can be…
